212: Applause-worthy cancer data, the long wait for Novavax, & the next FDA controversy
The Readout Loud
00:00
Madurna Vaccines
Materna has developed what they call a by valent vaxine, which is to say, it's m r n a. The company ran a trial in rolling, i think, upwards of 400 people to determine that it's by vail of axin the combo vaccine had a significantly stronger effect on antibodies. Madona doesn't have a munogenicity data, or at least didn't report any this week, on the currently circulating sub variance of omicron.
Transcript
Play full episode
